| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience |
|
Leukemia & Lymphoma |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study |
|
Leukemia Research |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
